GSK and ViiV Healthcare Sign an Exclusive License Agreement with NIH for its Investigational bNAb to Treat and Prevent HIV

GSK and ViiV Healthcare Signs an Exclusive License Agreement with NIH for its Investigational bNAb to Prevent HIV Infection

Shots:

  • NIAID, part of NIH to receive milestones and royalties on sales of N6LS. GSK and NIH to jointly identify & develop broadly neutralizing antibodies (bNAbs) including N6LS for providing the treatment & preventative options for HIV transmission
  • ViiV to initiate P-IIa study with material manufactured by the NIAID Vaccine Research Center and will lead to evaluation of efficacy, safety, tolerability, and PK profile of N6LS in adults living with HIV
  • N6LS is an antiviral bNAb, designed to bind to a specific site (gp120) on the surface of HIV, preventing its entry into uninfected immune system cells (CD4+ T-cells), thus the HIV replication is halted, and its transmission is prevented

Click here to­ read full press release/ article | Ref: GSK | Image: ViiV Healthcare